Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × Ramucirumab × Clear all
NCT00721162 2019-09-26

Study of Ramucirumab in Ovarian Cancer

Eli Lilly and Company

Phase 2 Completed
60 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡